| TMO |
Report |
Q2 adjusted EPS |
BEAT |
pred ~$5.82 vs. cons $5.71 |
MEDIUM |
| TMO |
Report |
Q2 revenue |
BEAT |
pred ~$11.82B vs. cons $11.70B |
MEDIUM |
| TMO |
Report |
Q2 organic revenue growth |
BEAT |
pred ~3.2% vs. cons 3.0% |
MEDIUM |
| TMO |
Guide |
FY2026 revenue guidance midpoint |
LOWER |
guide ~$47.55B vs. cons $47.70B (FY2026) |
MEDIUM |
| TMO |
Guide |
FY2026 adjusted EPS guidance midpoint |
UNCHANGED |
guide ~$24.90 vs. cons $24.88 (FY2026) |
MEDIUM |
| TMO |
Guide |
FY2026 organic revenue growth guidance midpoint |
UNCHANGED |
guide ~3.5% vs. cons 3.5% (FY2026) |
HIGH |
| TMO |
Guide |
FY2026 adjusted operating-margin expansion |
UNCHANGED |
guide ~70 bps vs. cons 70 bps (FY2026) |
MEDIUM |
| TMO |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.2% |
— |
MEDIUM |
| TMO |
Return |
5-day cumulative residual |
+1.6% (FADE) |
A clean organic-growth acceleration and EPS beat should drive the initial gain, but a mechanically lower FY2026 revenue guide from the microbiology divestiture implies pred ~$0.10 of out-period EPS-estimate reductions vs. cons ~$0.00, causing revisions to temper the five-day move. |
MEDIUM |